Clinical Trials in Illinois

Showing 13981-14000 of 19,692 trials

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

NCT00632541

Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.

Metastatic Breast Cancer

Hoosier Cancer Research Network18 participantsStarted Oct 2007

Galesburg, Illinois, United States • Evansville, Indiana, United States • Fort Wayne, Indiana, United States +7 more locations

TERMINATEDPhase 2111 miles

Study of Ruxolitinib in Colorectal Cancer Patients

NCT02119676

The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.

CRC (Colorectal Cancer)

Incyte Corporation396 participantsStarted Mar 2014

Chandler, Arizona, United States • Gilbert, Arizona, United States • Mesa, Arizona, United States +83 more locations

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Study of Ruxolitinib in Colorectal Cancer Patients

Find Trials by Condition in Illinois

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Expanded Access Program of Ponatinib

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Using the Canary Breathing System for Panic Disorder Patients

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

IV Iron for the Anemia of Traumatic Critical Illness

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants